Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
biomarker
cancer
hepatocellular carcinoma
prognosis
transarterial chemoembolization
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
09
2020
revised:
31
10
2020
accepted:
16
01
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
19
3
2021
Statut:
epublish
Résumé
Transarterial chemoembolization (TACE) represents a standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) or liver metastases. However, identification of the ideal candidates for TACE therapy remains challenging. The soluble urokinase plasminogen activator receptor (suPAR) has recently evolved as a prognostic marker in patients with cancer; however no data on suPAR in the context of TACE exists. Serum levels of suPAR were measured by an enzyme-linked immunosorbent assay in Serum levels of suPAR were significantly elevated in patients with liver cancer compared to healthy controls. Patients with or without an objective tumor response to TACE therapy had comparable levels of circulating suPAR. Importantly, baseline suPARs above the ideal prognostic cut-off value (5.39 ng/mL) were a significant prognostic marker for reduced overall survival (OS) following TACE. As such, patients with initial suPAR levels >5.39 ng/mL showed a significantly reduced median OS of only 256 days compared to patients with suPAR serum levels below the cut-off value (median OS: 611 days). In line with previous data, suPAR serum concentrations correlated with those of creatinine but were independent of tumor entity, leukocyte count, and C-reactive protein in multivariate analysis. Baseline suPAR serum levels provide important information on the postinterventional outcome of liver cancer patients receiving TACE.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Transarterial chemoembolization (TACE) represents a standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) or liver metastases. However, identification of the ideal candidates for TACE therapy remains challenging. The soluble urokinase plasminogen activator receptor (suPAR) has recently evolved as a prognostic marker in patients with cancer; however no data on suPAR in the context of TACE exists.
METHODS
METHODS
Serum levels of suPAR were measured by an enzyme-linked immunosorbent assay in
RESULTS
RESULTS
Serum levels of suPAR were significantly elevated in patients with liver cancer compared to healthy controls. Patients with or without an objective tumor response to TACE therapy had comparable levels of circulating suPAR. Importantly, baseline suPARs above the ideal prognostic cut-off value (5.39 ng/mL) were a significant prognostic marker for reduced overall survival (OS) following TACE. As such, patients with initial suPAR levels >5.39 ng/mL showed a significantly reduced median OS of only 256 days compared to patients with suPAR serum levels below the cut-off value (median OS: 611 days). In line with previous data, suPAR serum concentrations correlated with those of creatinine but were independent of tumor entity, leukocyte count, and C-reactive protein in multivariate analysis.
CONCLUSION
CONCLUSIONS
Baseline suPAR serum levels provide important information on the postinterventional outcome of liver cancer patients receiving TACE.
Identifiants
pubmed: 33732882
doi: 10.1002/jgh3.12501
pii: JGH312501
pmc: PMC7936623
doi:
Types de publication
Journal Article
Langues
eng
Pagination
356-363Informations de copyright
© 2021 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Semin Intervent Radiol. 2017 Jun;34(2):145-166
pubmed: 28579683
Cancer Res. 1996 Aug 1;56(15):3597-604
pubmed: 8758932
Int J Mol Sci. 2018 Jun 14;19(6):
pubmed: 29899223
Intensive Care Med. 2012 Sep;38(9):1418-28
pubmed: 22706919
J Cell Biochem. 2004 May 1;92(1):178-88
pubmed: 15095413
Surg Clin North Am. 2020 Jun;100(3):551-563
pubmed: 32402300
J Intern Med. 2013 Jul;274(1):86-100
pubmed: 23432143
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Gut. 2015 Apr;64(4):589-600
pubmed: 24848264
Carcinogenesis. 2019 Aug 22;40(8):947-955
pubmed: 30805627
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
Oncotarget. 2018 Jun 5;9(43):27027-27038
pubmed: 29930748
Gastroenterology. 2018 Dec;155(6):1951-1966.e26
pubmed: 30165047
BMC Cancer. 2006 Aug 18;6:211
pubmed: 16916471
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Abdom Radiol (NY). 2018 Jan;43(1):13-25
pubmed: 28647765
Anticancer Res. 2020 Jan;40(1):1-7
pubmed: 31892548
Langenbecks Arch Surg. 2015 Aug;400(6):641-59
pubmed: 26088872
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
JHEP Rep. 2020 Jan 31;2(2):100080
pubmed: 32140677
J Hepatocell Carcinoma. 2017 Jul 27;4:105-110
pubmed: 28795053
Liver Int. 2015 Feb;35(2):601-7
pubmed: 25348952
Crit Care. 2011;15(1):R63
pubmed: 21324198
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
World J Clin Oncol. 2017 Jun 10;8(3):190-202
pubmed: 28638789
Cancer. 2012 Jan 1;118(1):147-56
pubmed: 21713764
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597337
Liver Int. 2014 Oct;34(9):1330-9
pubmed: 24575897
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Hepatology. 2013 Jun;57(6):2261-73
pubmed: 23316013
Int J Cancer. 2009 Apr 15;124(8):1860-70
pubmed: 19123477
J Hepatol. 2017 Oct;67(4):749-757
pubmed: 28668580
Expert Opin Pharmacother. 2011 May;12(7):1057-73
pubmed: 21470073
Med Oncol. 2013 Jun;30(2):540
pubmed: 23512428
Brain Res Mol Brain Res. 2001 Jul 13;91(1-2):96-103
pubmed: 11457496